[1-(2,2,2-三氟乙基)哌啶-4-基]甲醇 | 831169-69-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: [1-(2,2,2-三氟乙基)哌啶-4-基]甲醇
• 英文名称: (1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanol
• 英文别名: [1-(2,2,2-Trifluoroethyl)piperidin-4-yl]methanol
• CAS: 831169-69-8
• 化学式: C₈H₁₄F₃NO
• mdl: MFCD16153513
• 分子量: 197.2
• InChiKey: CJUSUBQANRFWAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  [1-(2,2,2-三氟乙基)哌啶-4-基]甲醇 以92的产率得到1-(2,2,2-Trifluoroethyl)piperidine-4-carbaldehyde
  参考文献：
  名称：

  [EN] SYNTHESIS OF INHIBITORS OF EZH2
  [FR] SYNTHÈSE D'INHIBITEURS D'EZH2

  摘要：

  本文提供了一种合成EZH2抑制剂的方法。

  公开号：

  WO2018075598A1
• 作为产物：
  描述：

  4-哌啶甲酸甲酯 在 三氟化硼四氢呋喃络合物 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 [1-(2,2,2-三氟乙基)哌啶-4-基]甲醇
  参考文献：
  名称：

  Design of fluorinated 5-HT4R antagonists: Influence of the basicity and lipophilicity toward the 5-HT4R binding affinities

  摘要：

  Analogues of potent 5-HT4R antagonists possessing a fluorinated N-alkyl chain have been synthesized in order to investigate the effect of the resulting change in basicity and lipophilicity on the affinity and selectivity profile. We demonstrate that for this series, the affinity is decreased with decreased basicity of the piperidine's nitrogen atom. In contrast, the resulting increase in lipophilicity has minimal impact on binding affinity and selectivity. 3,3,3-Trifluoropropyl and 4,4,4-trifluorobutyl derivatives 6d and 6e have shown to bind to the 5-HT4R while maintaining their pharmacological profile and selectivity toward other 5-HT receptors. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.08.061

文献信息

• [EN] TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS<br/>[FR] INHIBITEURS DE PRMT5 DÉRIVÉS DE TÉTRAHYDROISOQUINOLÉINE
  申请人：CTXT PTY LTD

  公开号：WO2016034673A1

  公开（公告）日：2016-03-10

  A compound of formula I wherein: n is 1 or 2: p is 0 or 1; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.

  式I的化合物，其中：n为1或2；p为0或1；R1可选地为一个或多个卤素或甲基基团；R2a和R2b分别选自以下组：(i) F；(ii) H；(iii) Me；和(iv) CH2OH；R2c和R2d分别选自以下组：(i) F；(ii) H；(iii) Me；和(iv) CH2OH；R3a和R3b分别选自H和Me；R4为H或Me；R5为H或Me；R6a和R6b分别选自H和Me；A为(i)可选地取代的苯基；(ii)可选地取代的萘基；或(iii)可选地取代的C5-12杂环基。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：GLAXO GROUP LTD

  公开号：WO2013160418A1

  公开（公告）日：2013-10-31

  The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORγ.

  本发明涉及新型视黄醛相关孤儿受体γ（RORγ）调节剂，其制备方法，含有这些调节剂的药物组合物，以及它们在治疗由RORγ介导的炎症性、代谢性和自身免疫性疾病中的应用。
• NOVEL COMPOUNDS
  申请人：Glaxo Group Limited

  公开号：US20150080369A1

  公开（公告）日：2015-03-19

  The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORγ.

  本发明涉及新型视黄醛酸相关孤儿受体γ（RORγ）调节剂，其制备方法，含有这些调节剂的药物组合物，以及它们在治疗由RORγ介导的炎症性、代谢性和自身免疫疾病中的应用。
• Compounds
  申请人：Glaxo Group Limited

  公开号：US09428452B2

  公开（公告）日：2016-08-30

  The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORγ.

  本发明涉及新型视黄醇相关孤儿受体γ（RORγ）调节剂，其制备方法，含有这些调节剂的制药组合物，以及它们在治疗由RORγ介导的炎症性、代谢性和自身免疫性疾病中的应用。
• Synthesis of inhibitors of EZH2
  申请人：Constellation Pharmaceuticals, Inc.

  公开号：US10457640B2

  公开（公告）日：2019-10-29

  Provided herein are synthetic methods for the preparation of EZH2 inhibitors.

  本文提供了制备 EZH2 抑制剂的合成方法。